Congratulations to portfolio company Regenosine on receiving a $1.67M NIH NIAMS Phase II SBIR grant to commercially develop their disease modifying osteoarthritis drug.
Tech Council Ventures featured four companies that are making waves in their industries
Tech Council Ventures is excited to share the highlights from its recent webinar featuring four exceptional Fund II portfolio companies....
